CA-DNSC/DRUPA-2016
Diversified Nano Solutions Corporation (DNSC) will be exhibiting digital INKS unlimited at Drupa “Touch the Future” 2016, May 31 – June 10, 2016, in Düsseldorf, Germany, at Halle 2-B05
Based in San Diego, California, with manufacturing facilities in the US and Europe, DNSC specializes in developing and manufacturing digital inks, nano materials, and fluids for high-resolution, high-performance digital inkjet printing. DNSC provides unique ink development services, research, and turn-key ink supply and fulfillment solutions reaching end users, resellers and, printer manufacturers worldwide. DNSC has developed an extensive product line under the x-nano™ brand, providing a range of solutions including high-quality, low-cost black & color dye inks (Value-Series), pigment inks (Elite Series), special ultra-fast dry inks (S-Series), magnetic MICR inks (K-Series), invisible fluorescent color (RGB) inks, infrared-absorbing inks (I-Series), and special inks for food grade, textile, and special effect applications (F-, T-, and X-Series). The company’s digital inks target dot-on-demand inkjet applications based on thermal and piezo print heads using aqueous, oil, energy-curable (UV/LED), and eco-solvent based inks.
DNSC offers a wide array of inkjet inks at unprecedented low cost supporting direct mail, transactional, transpromo, books, catalogs/magazines, ticket, tags, labels, and graphics printing applications. DNSC is uniquely positioned to help users create differentiated, high-value output through personalization using x-nano™ special effect inks such as magnetic (MICR), invisible fluorescent, spot color, and security inks for thermal & piezo digital inkjet platforms.
The company supports its ink offerings with accessories to facilitate and aid x-nano™ ink use and applications. These include specialty substrates, UV display lights, INKVERSE™ “Infinite Ink Infuser” – a revolutionary and cost-effective way to adopt and deliver digital inks to existing and new inkjet systems via a continuous delivery ink supply system, and TransChrome™ – an Invisible Color Image Generator to transform CMYK into UV fluorescent RGB output, and more.
At Drupa 2016, DNSC introduces X-Series, a new family of pigment powders and dispersions to serve as base components for custom development and production of ink, paint, paste, dispersion, gel, cream, and powder. These special effect base materials photo-luminesce, fluoresce, absorb IR, and change color with light or heat. X-Series materials have highly customizable properties that allow for various exceptionally unique market applications associated with digital and non-digital printing applications.
DNSC will be showcasing its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial, and industrial inkjet space.
Visit Halle 2-B05 and discover DNSC digital INKS unlimited!
View source version on businesswire.com: http://www.businesswire.com/news/home/20160531005263/en/
Contact:
Diversified Nano Solutions Corporation
Kimberly Villwock
US:
+1.858.924.1005
EU: +41.41 874 08 50
kimberlyv@diversifiednano.com
info@diversifiednano.com
www.diversifiednano.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom